Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorde
The US regulator has approved a drug to treat low potassium as the first generic with the Competitive Generic Therapy (CGT) designation, marking the beginning of a new strategy and FDA effo
